Advertisements

Аспаркам

Quick links to important sections

Аспаркам

Selected form

Advertisements
Advertisements

Method of action: Mineral Supplements, Tonics

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Аспаркам

Quick Facts

Property Description
Active Ingredient Magnesium Aspartate, Potassium Aspartate
Form Tablet (Oral), Solution for Infusion (Parenteral)
Pharmacological Class Metabolic Agent, Source of Macroelements
General Purpose Maintenance of Electrolyte Balance
Origin Synthetic salts of L-Aspartic Acid

1. Аспаркам: Definition and Pharmacological Classification

Аспаркам is a combination drug that functions as a metabolic agent and a source of macroelements, intended to supply the body with two crucial intracellular cations: potassium (K^+) and magnesium (Mg^2+). The product is chemically identified as Potassium and Magnesium Asparaginate, a generic name structurally identical to other combination formulations, such as Panangin. Its function as an electrolyte replenisher is to restore electrolyte levels through the role of magnesium and potassium aspartates.

The primary active ingredients are Potassium Aspartate and Magnesium Aspartate, which are synthetically derived salts of the natural amino acid L-Aspartic Acid. The drug is designed as a combination agent for optimizing mineral utilization due to the close physiological link between magnesium and potassium homeostasis.

2. Composition, Forms, and Delivery Mechanism

This preparation is available in two distinct dosage forms: an oral solid dosage form (tablet) and a parenteral liquid dosage form (solution for infusion). This allows for administration via the oral or parenteral routes, respectively. The use of the aspartate anion is integral to the mechanism, acting as a transport system facilitator that promotes the efficient movement of the potassium and magnesium ions across cell membranes. The pharmacological action of the aspartate anion promotes the delivery of these essential cations to sites where they are needed for cellular energy and electrical function.

3. General Purpose and Role in Ion Homeostasis

The general purpose of this medication is to maintain electrolyte balance and support the stability of cell function. By restoring adequate levels of potassium and magnesium, the drug contributes to overall metabolic processes and is particularly vital for the stability of electrically active tissues. A typical scenario for its use involves general support for the cardiovascular system when ion deficiencies are identified, as its primary function ensures the proper transmission of nerve impulses and sustains the function of the heart muscle.

Advertisements

What side effects are possible with Аспаркам?

Possible Side Effects and Safety Information

The safety profile of Аспаркам, which contains potassium and magnesium aspartate, is documented based on official government regulatory data and clinical experience. Adverse reactions are classified by the body system affected and their reported frequency.

Adverse Reactions by System and Frequency

System-Organ Class Frequency Key Adverse Reactions
Gastrointestinal Disorders Rare Nausea, vomiting, diarrhea, abdominal discomfort
Cardiac Disorders Not Known Atrioventricular conduction disorder, paradoxical reactions (increased arrhythmia)
Metabolism and Nutrition Very Rare/Not Known Hyperkalemia (high potassium), Hypermagnesemia (high magnesium)
Immune System Rare Allergic reactions

Note: Rare events occur in ge 1/10,000 to < 1/1,000 users. Frequencies classified as Not Known are those that cannot be estimated from available data.

Serious Safety Considerations

The most significant risks documented in the official safety information include hyperkalemia and hypermagnesemia, which can lead to serious cardiac arrhythmias or atrioventricular conduction disorder. The risk of these serious events is higher when the medication is administered rapidly or in higher doses.

Safety Restrictions and Monitoring

Formal restrictions for use, known as contraindications, strictly prohibit the use of Аспаркам in patients with pre-existing conditions that increase risk. These include:

  • Pre-existing Hyperkalemia or Hypermagnesemia
  • Severe Renal Impairment (kidney failure)
  • Certain types of Heart Block (e.g., AV block III degree)
  • Cardiogenic Shock accompanied by low blood pressure

Official safety guidance requires professional monitoring of serum potassium and magnesium levels during the course of therapy, particularly when co-administered with other medications that affect potassium balance.

Advertisements

Overdose and Emergency Response

Overdose with Potassium Aspartate and Magnesium Aspartate (Аспаркам) is defined by the toxic effects of excessive potassium (hyperkalemia) and magnesium (hypermagnesemia), as documented in official regulatory information. Documented clinical manifestations begin with gastrointestinal distress, such as nausea and vomiting, and progress to neuromuscular signs including significant muscle weakness and depressed deep tendon reflexes.

Life-Threatening Manifestations

The official overdose profile focuses on risks that are potentially severe or life-threatening, primarily impacting the cardiovascular and respiratory systems. Serious outcomes include critical electrocardiographic (ECG) changes, profound hypotension, severe cardiac arrhythmias leading to cardiac arrest, and escalating respiratory depression which may result in paralysis.

Immediate Emergency Actions

Regulatory guidance strictly states that immediate medical attention is required for any suspected overdose or the onset of severe symptoms. This includes contact with emergency services for symptoms indicative of acute cardiotoxicity or severe breathing difficulties. Management procedures, as described in official documents, often involve the administration of a calcium salt to stabilize cardiac function and employing measures such as intravenous insulin/dextrose or diuresis to manage ion levels.

Population-Specific Risk

The official labeling emphasizes that the risk of severe hyperkalemia and hypermagnesemia is significantly amplified in patients with impaired renal function, as the body loses the ability to effectively excrete the excess ions, making them highly vulnerable to these severe effects.

Advertisements

Therapeutic Uses of Аспаркам

What Аспаркам treats: Main Uses and Benefits

This combination preparation is generally used to address symptoms related to systemic imbalance of essential intracellular minerals. It is primarily considered relevant for correcting deficits known as hypokalemia (low potassium) and hypomagnesemia (low magnesium). This therapy is commonly used to support the restoration of these necessary macroelements, which assists with stable physiological function.

The medication is applied in scenarios where patients experience noticeable physical distress or instability. This includes individuals with chronic heart disease and heart failure, as well as those managing specific cardiac rhythm disturbances, and patients with neuromuscular symptoms like muscle weakness and cramping due to mineral loss. The medication provides targeted support during phases when symptoms become more noticeable, such as after the use of saluretic diuretics or during digitalis therapy.

“The medication may assist with managing symptomatic manifestations related to electrolyte depletion, helping to ease the overall physical burden of distress.”


Quick Fact: Relief for Deficiency Symptoms

Domain Conditions/Symptoms Managed
Cardiology Support for electrical stability; managing associated cardiac rhythm disturbances.
Metabolism Correction of Hypokalemia and Hypomagnesemia; management of deficiency symptoms.
Neuromuscular Easing episodes of muscle weakness and involuntary cramping.

Regulatory References

  1. National Institutes of Health (NIH) StatPearls on Magnesium
Advertisements

Eligibility and Restrictions for Use

Asparkam, a medication containing potassium aspartate and magnesium aspartate, is primarily used to address deficiencies of these electrolytes, often associated with conditions like cardiac arrhythmias, ischemic heart disease, and heart failure. It may also be used for hypokalemia and hypomagnesemia.


Contraindications and Precautions

Asparkam is not suitable for all individuals. Due to the risk of dangerously high electrolyte levels, it is contraindicated in patients with:

  • Hyperkalemia (excessive potassium in the blood)
  • Hypermagnesemia (excessive magnesium in the blood)
  • Acute and chronic kidney failure
  • Shock (including cardiogenic shock)
  • Severe dehydration
  • Addison's disease (adrenal insufficiency)
  • Severe myasthenia gravis

Caution is advised in patients with heart conduction disturbances (e.g., atrioventricular block) and in those taking other medications that increase potassium levels (such as certain diuretics or ACE inhibitors). Pregnant and breastfeeding patients should consult a healthcare provider to weigh the benefits against the risks. Asparkam should only be used under a physician's supervision to ensure it is safe for the patient's specific health condition and to avoid potentially dangerous electrolyte imbalances.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Аспаркам (Potassium Aspartate and Magnesium Aspartate) documents interactions primarily categorized by two mechanisms: additive pharmacodynamic risk and pharmacokinetic absorption interference.

Contraindicated and High-Risk Combinations

The co-administration of Аспаркам with Potassium-Sparing Diuretics (such as spironolactone, amiloride, or triamterene) is formally contraindicated. This restriction is due to the severe, additive pharmacodynamic effect that significantly increases the risk of hyperkalemia (dangerously high potassium concentration). Other potassium supplements are also typically prohibited for the same reason.

Further combinations requiring close monitoring include ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), all of which may increase the risk of hyperkalemia. Co-administration with other Magnesium-Containing Products (e.g., antacids or laxatives) increases the potential for hypermagnesemia.

Mandatory Timing Separation Rules

Oral administration of Аспаркам (tablet) requires specific timing separation when taken with certain agents to prevent reduced drug exposure. The magnesium component interferes with the gastrointestinal absorption of drugs sensitive to chelation, resulting in decreased efficacy of the co-administered agent. For this reason, oral forms of Tetracycline and Fluoroquinolone Antibiotics, Bisphosphonates, and Oral Iron Preparations must be separated from Аспаркам by an interval of 2 to 4 hours.

Population-Specific Interaction Note

The interaction risk leading to hyperkalemia and hypermagnesemia is heightened in patients with Renal Impairment due to the reduced ability to clear both active ions.

Advertisements

Mechanism of Action

Аспаркам functions by supplying essential potassium (K^+) and magnesium (Mg^2+) cations, delivered via the readily utilized aspartate vehicle. The primary action involves maintaining the optimal intracellular concentration gradients of these electrolytes. Magnesium acts as an indispensable cofactor for numerous enzymes, including those critical for ATP synthesis and the subsequent energy transfer processes within the cell.

The presence of K^+ is fundamental for establishing and regulating the resting membrane potential across the membranes of excitable cells, notably myocytes and neurons. This function is mediated by its influence on the activity of the sodium-potassium pump (Na^+/K^+-ATPase), which is an essential modulator of the electrochemical gradient.

By sustaining appropriate K^+ and Mg^2+ levels, the compounds support the normal electrical properties of the myocardium. Magnesium further acts as a cellular calcium channel antagonist, modulating the transmembrane flux of calcium ions (Ca^2+) required for the excitation-contraction coupling process. This combined activity regulates the electrophysiological balance within cardiac tissue, supporting cellular integrity and metabolic stability.

Advertisements

Dosage and Administration Information

The administration of Аспаркам (Potassium and Magnesium Aspartate) is strictly guided by protocols defined by its two dosage forms: the oral film-coated tablet and the solution for intravenous infusion.

Oral Regimen and Administration

The standard adult dosing schedule for tablets is typically one to two tablets taken three times daily (TID). Where indicated, the maximum daily dose may be increased, allowing for up to three tablets per dose. Proper administration requires that the tablets be swallowed whole, without chewing, and are recommended for intake after meals.

An important procedural constraint governs co-administration: an interval of at least three hours must elapse between taking the oral tablets and consuming certain other oral medications, such as iron salts or oral tetracyclines, to prevent potential absorption interference.

Parenteral Protocol

The solution for infusion is reserved for use in a specialized medical environment. The parenteral protocol mandates that two ampoules of the solution concentrate must first be diluted in 50–100 mL of 5% glucose solution. The resultant preparation must then be delivered via slow intravenous injection or slow drip infusion. This specific preparation and slow delivery rate are mandatory procedural conditions that govern the administration of the solution.

Advertisements

Recent Clinical Evidence

Аспаркам: Recent Clinical Evidence

Research involving the combination of potassium and magnesium aspartate, often referred to by its established trade names, focuses on the role of these essential electrolytes in metabolic and cardiovascular health. As both potassium and magnesium are vital for cell function and the regulation of nerve and muscle impulses, studies primarily investigate their utility in conditions associated with electrolyte imbalance.

Explorations in Cardiovascular Health

Clinical research has explored the relationship between adequate potassium and magnesium intake and cardiac function, particularly in patients with existing heart conditions or electrolyte disturbances. In specific, small-scale trials have evaluated whether the administration of potassium magnesium aspartate may influence the incidence of certain arrhythmias (irregular heartbeats) when used alongside routine therapies for coronary artery disease. Findings from some of these studies suggested a reduction in frequent premature beats and noted changes in oxidative stress markers.

Metabolism and Performance Studies

Studies have also examined the compound's effect on general muscle metabolism and physical endurance. While some older reports suggested potential improvement in muscle performance, later controlled studies focusing on short-term intensive static exercise did not observe a significant increase in force production or endurance time in human volunteers or altered metabolic parameters in animal models. The evidence remains limited and mixed regarding a definitive benefit in enhancing athletic performance.

Safety and Pharmacokinetic Profile

The aspartate salt form is frequently selected for its reported high absorption profile compared to some inorganic salts of magnesium. Phase I trials focus on the tolerability of the compound across various doses and the documentation of adverse events. Further research is necessary to fully establish its role in complex clinical settings and to understand its long-term effects on various patient populations.

Key Studies & References

  1. [Therapy of cardiac arrhythmias. Clinical significance of potassium- and magnesium aspartate in arrhythmias]
  2. The Effect of Magnesium on Reperfusion Arrhythmias in STEMI Patients, Treated With PPCI. A Systematic Review With a Meta-Analysis and Trial Sequential Analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Аспаркам (FAQ)

Q: Why do bodybuilders or athletes sometimes talk about using Аспаркам?

A: Studies have explored the role of this combination product in general muscle metabolism and physical endurance. While some reports suggested a benefit, more recent controlled research focusing on short-term intensive exercise did not observe a significant increase in muscle strength or endurance time in human volunteers. Official information indicates the evidence remains limited and mixed regarding its effectiveness for enhancing athletic performance.

Q: Is it normal to feel a mild laxative effect when taking Аспаркам?

A: Gastrointestinal issues, such as nausea, diarrhea, and abdominal discomfort, are documented as adverse reactions, although they are generally reported as rare events. High doses of magnesium-containing products, including this one, can cause a laxative effect. Concerns about persistent or severe side effects should always be discussed with a healthcare professional.

Q: Is Аспаркам a prescription-only medicine or over-the-counter?

A: The magnesium aspartate component itself is often available over-the-counter (OTC) as a supplement. However, the combination drug Аспаркам is typically regulated for use under a physician's supervision, especially in its intravenous form. Determining the specific regulatory status of the oral tablet requires checking the local health authority guidance in your region.

Q: What is the difference between Аспаркам and Panangin?

A: The official active ingredients, potassium aspartate and magnesium aspartate, are chemically identical in both products. Panangin is a common brand name for this combination, and Аспаркам is either a generic name or a separate brand name formulation. Any potential differences are typically related to regulatory context or non-active ingredients.

Q: Are there any long-term studies on the safety of using Аспаркам?

A: Clinical research has examined the short-term tolerability of the compound and its role in acute support for heart and metabolic health. However, official information notes that further research is necessary to fully establish its long-term effects when used by various patient populations.

Q: Does Аспаркам help with leg cramps or muscle spasms?

A: Magnesium is a vital element for proper muscle contraction and relaxation. While potassium and magnesium are used to address electrolyte imbalances, the official regulatory indications for the product itself do not explicitly list the treatment of general leg cramps or muscle spasms as an approved use.

Q: Is Аспаркам safe for use during pregnancy or breastfeeding?

A: Regulatory guidance indicates that patients who are pregnant or breastfeeding need to have the benefits and potential risks carefully assessed by a healthcare provider. There is no in-depth clinical data on harmful effects when the product is used during these periods.

Q: Does Аспаркам interact with common painkillers like Paracetamol?

A: According to regulatory information, no clinically significant interaction has been established between the active components of this medicine and Paracetamol (acetaminophen). It is important for a healthcare provider to have a complete list of all medicines and supplements a person is taking for a comprehensive safety review.

Q: Can taking Аспаркам affect the results of blood tests?

A: Yes, taking this medication will affect blood tests. Because the drug is intended to supply potassium and magnesium, safety guidance requires that a healthcare professional monitor serum (blood) potassium and magnesium levels during the course of therapy.

Q: Does Аспаркам interact with common multivitamins?

A: Caution is advised when taking this medication alongside other magnesium-containing products, which can include some multivitamins or laxatives, as this increases the potential for hypermagnesemia (dangerously high magnesium levels). The potential need for co-administration should be reviewed with a healthcare professional.

Q: Why is potassium supplementation sometimes dangerous for certain people?

A: Potassium supplementation is dangerous for people who already have conditions like severe kidney failure or hyperkalemia (excessive potassium in the blood). In these patients, the body cannot clear the extra potassium, leading to severe hyperkalemia, which can cause serious and potentially life-threatening heart rhythm problems.

Q: Can Аспаркам be crushed or split if the tablet is hard to swallow?

A: The official administration protocol is very specific: the oral tablets must be swallowed whole and not crushed, split, or chewed. This requirement ensures the correct release and absorption of the medicine as intended.

Q: Is it better to take Аспаркам in the morning or at night?

A: Official guidance on how to take the medicine does not specify morning or night. It simply advises that the tablets be taken multiple times daily and recommends intake after meals.

Q: Does Аспаркам have any known interactions with herbal supplements?

A: Specific interactions with the vast range of herbal supplements are generally not documented in the official regulatory product labels. Patients are generally required to inform their healthcare provider about all herbal and complementary medicines being used.

Q: Is Аспаркам affected by hot or cold weather conditions?

A: To maintain quality and effectiveness, the drug has specific storage requirements. The un-prepared product must not be stored above 25 C and should be kept in its original, sealed packaging.

Q: How does the bioavailability of Аспаркам compare to dietary minerals?

A: The aspartate salt form used in this medication is frequently selected because research has reported that it has a high absorption profile compared to certain inorganic (non-aspartate) forms of magnesium. Direct, standardized comparison to minerals found in regular food is complex and not included in regulatory labeling.

Advertisements

How should Аспаркам be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents define specific storage and stability constraints for medicines containing magnesium and potassium aspartate, which are the active components of Asparkam. These requirements ensure product quality and integrity before and during use.

Condition Requirement (Unreconstituted Product)
Maximum Storage Temperature Do not store above 25 C.
Packaging Keep in original sealed container (e.g., paper/aluminium/polyethylene sachets).
Shelf-Life Up to 3 years, if stored correctly.

For the medicine once prepared (reconstituted):

  • Prepared Solution Stability: The solution must be stored below 25 C and should be used within 24 hours of preparation.
  • Handling: The powder is intended to be dissolved in a liquid (water, tea, or juice).

Disposal: Any unused medicinal product or waste material must be disposed of strictly in accordance with local waste requirements for pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Аспаркам found in:

A-Z Index: